Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends SCPS vs. CALA, VAXX, AMPE, ARDS, STAB, CMRA, EVLO, GNCA, EFTR, and ATNFWShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Calithera Biosciences (CALA), Vaxxinity (VAXX), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Genocea Biosciences (GNCA), eFFECTOR Therapeutics (EFTR), and 180 Life Sciences (ATNFW). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Calithera Biosciences Vaxxinity Ampio Pharmaceuticals Aridis Pharmaceuticals Statera Biopharma Comera Life Sciences Evelo Biosciences Genocea Biosciences eFFECTOR Therapeutics 180 Life Sciences Scopus BioPharma (NASDAQ:SCPS) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Does the MarketBeat Community believe in SCPS or CALA? Calithera Biosciences received 339 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 57.21% of users gave Calithera Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesCalithera BiosciencesOutperform Votes34157.21% Underperform Votes25542.79% Which has stronger valuation & earnings, SCPS or CALA? Scopus BioPharma has higher earnings, but lower revenue than Calithera Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ACalithera Biosciences$9.75M0.00-$39.65MN/AN/A Is SCPS or CALA more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Calithera Biosciences N/A N/A N/A Does the media refer more to SCPS or CALA? In the previous week, Calithera Biosciences had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Calithera Biosciences Neutral Which has more risk and volatility, SCPS or CALA? Scopus BioPharma has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500. SummaryScopus BioPharma and Calithera Biosciences tied by winning 3 of the 6 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10,000.00$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E RatioN/A10.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book0.005.474.674.68Net Income-$11.61M$153.61M$119.07M$226.08M7 Day PerformanceN/A-2.00%-1.83%-1.04%1 Month PerformanceN/A-7.47%-3.62%1.04%1 Year PerformanceN/A31.80%31.63%26.28% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$13,000.00N/A0.009CALACalithera BiosciencesN/A$0.01+2.8%N/A-76.0%$36,000.00$9.75M0.0060VAXXVaxxinityN/A$0.00flatN/A-100.0%$25,000.00$70,000.000.0090AMPEAmpio PharmaceuticalsN/A$0.01+∞N/A-99.6%$11,000.00N/A0.0020Gap DownARDSAridis PharmaceuticalsN/AN/AN/AN/A$10,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A+0.0%$10,000.00$1.49M0.0020CMRAComera Life SciencesN/A$0.00flatN/A-99.5%$9,000.00$630,000.000.002EVLOEvelo BiosciencesN/A$0.00-66.7%N/A-99.7%$9,000.00N/A0.00120News CoverageGap DownGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastEFTReFFECTOR Therapeutics1.2792 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Negative NewsATNFW180 Life SciencesN/A$0.01-11.1%N/A-25.0%$0.00N/A0.007Gap Down Related Companies and Tools Related Companies Calithera Biosciences Competitors Vaxxinity Competitors Ampio Pharmaceuticals Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Comera Life Sciences Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors eFFECTOR Therapeutics Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
